MafA CRISPR/Cas9 KO Plasmid (h): sc-401480
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MafA CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MafA genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MafA Antibody (F-6): sc-390491
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MafA CRISPR/Cas9 KO Plasmid (h) | sc-401480 | 20 µg | $397.00 |
Overview
MAFA encodes the MafA transcription factor, a basic leucine zipper protein that binds MAF recognition elements to regulate gene expression programs involved in cellular differentiation and stimulus-responsive transcription. In human pancreatic islet biology, MafA is linked to regulation of insulin gene transcription and broader networks that coordinate glucose-responsive signaling, secretory pathway function, and maintenance of endocrine cell identity. Altered MAFA activity has been associated with dysregulated beta-cell gene expression states and impaired insulin production, making it relevant to studies of diabetes-related mechanisms and islet stress responses. Beyond the pancreas, MafA-dependent transcriptional control provides a model for investigating tissue-specific enhancer usage and transcription factor–driven metabolic gene regulation.
MafA CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MAFA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MAFA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MAFA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MafA protein expression.
This CRISPR knockout system enables efficient generation of MAFA-deficient cell models for investigation of MafA signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MAFA exon(s) critical for MafA function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MAFA genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MafA CRISPR/Cas9 KO Plasmid (h) and MafA CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MAFA locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MafA HDR Plasmid (h) and MafA HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MAFA homology arms to support homology-directed repair at defined MAFA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.